China SXT Pharmaceuticals, Inc. revenue by segment SXTC
Annual
Quarterly
China SXT Pharmaceuticals, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2026, which ended Mar 31, 2026 was Regular TCMP at $1.1 million, 95% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Mar 31, 2026
|
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
FY 2021
Mar 31, 2021
|
FY 2020
Mar 31, 2020
|
FY 2019
Mar 31, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
1
|
2
|
2
|
2
|
3
|
5
|
5
|
7
|
| Regular TCMP |
1
-25.0%
share 95.0%
|
1
share 82.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Advanced TCMP |
0
-80.8%
share 4.4%
|
0
share 14.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Others |
0
-82.2%
share 0.6%
|
0
share 2.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Revenue From Related Parties |
0
-99.0%
share 0.0%
|
0
-84.5%
share 0.2%
|
0
-17.4%
share 1.4%
|
0
-90.1%
share 1.7%
|
0
share 13.0%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SXTC (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- Taizhou
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1723980
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.